Nucleai has partnered with Sirona Dx to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology firms for drug development.

Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.

The FDA's guidance emphasises the potential of NGS methods to mitigate safety risks associated with therapies incorporating genome editing.

Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

An analyst noted that this uptick may be a case of “frontloading”, meaning the EU’s 2026 pharma export growth outlook may not be as strong.

Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

Leading pharmaceutical industry players will convene at PHARMAP Congress 2026 on 20-21 April in the Netherlands, bringing together experts from manufacturing and packaging to quality assurance and ...

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.